GENERIC NAME M A G N E S I U M S U L F A T E

BRAND NAME E L I N M A G N E S I U M S U L F A T E

CLASIFICATION Central nervous system drugs

ACTION May decrease acetylchol ine release by impulses, but anticonvul sant mechanis m is unknown.

INDICATION

CONTRAINDICATION

ADVERSE REACTION Flushing, sweating, hypotension, muscular weakness, sedation, confuse. Neuromuscu lar blocking agents. An excess of Mg ions in the body fluid causes direct depressant effect on skeletal muscles, decrease release of acetylcholine by motor nerve impulses and reduced sensitivity of the motor and plate to acetylcholine .

NURSING CONSIDERATION

Use as an Patients with heart anticonvulsant block or myocardial . Lowers damage intracranial pressure. For hypomagnesa emia in patients receiving total parenteral nutrition(TPN). Prevention and control of seizures in toxemia (preeclampsia or eclampsia), acute nephritis in children and other conditions like epilepsy, glomerulonep hritis,or hypothyroidis m. Electrolyte additive. Inhibits uterine contractions in tocolysis (preterm labor). Also used for the treatment of life threatening

Assess patients condition before therapy and reassess regularly thereafter to monitor drug effectiveness. Monitor respiration: RR(16/minute). Watch for respiratory depression and signs of heart block. Monitor renal status. Assess input- output ratio, output (100ml 4 hours before each dose). Monitor for possible drug induced adverse reactions CNS: Drowsiness, depressed reflexes, flaccid paralysis, hypothermia.

arythmias such as atypical ventricular tachycardia (torsades de pointes). Other uses; counteracts intense muscle stimulating effects of barium poisoning

CV: Hypotension, flushing, circulatory collapse, depressed cardiac function, heart block. Metabolic: hypocalcemia Respiratory: paralysis Skin: diaphoresis

Monitor for signs of magnesium toxicity: disappearance of knee-jerk and patellar reflexes are signs of early magnesium toxicity. Assess prior drug history; there are many drug interactions Assess patients and familys knowledge of drug therapy

Dosage: 8 ml of 50% solution Route: IV Frequency: Every hour

GENERIC NAME

BRAND NAME E L I N O X Y T O C I N

CLASSIFICATION

ACTION Acts directly on myofibrils , producin g uterine contractio n: Stimulate s milk injection by the breast

INDICATION Initiation or improvement of uterine contraction to achieve early vaginal delivery for maternal or fetal reasons ( IV); management of inevitable or incomplete abortion (IV); stimulation of uterine contractions during first stage of labor (IV); stimulation reinforcement of labor, as in selected cases of uterine inertia (IV). Control of postpartum bleeding or hemorrhage (IV,IM);

CONTRAINDICATION Pregnancy (category X); no indication for use in first trimester unless related to spontaneous of induced abortion. Hypersensitivity, pregnancy-induced hypertension, cephalopelvic disproportion, fetal distress, hypertonic uterus

ADVERSE REACTION Seizures, titanic contractions, hypotension, hypertension , dysrhythmia s, increase pulse, bradycardia, tachycardia, premature ventricular contractions, jaundice, hypoxia, intracranial hemorrhage, anorexia, nausea, vomiting, constipation, abruptioplac entae, Decrease uterine blood flow, increase hyperbilirubinemia , rush, asphyxia

NURSING CONSIDERATION
Monitor blood pressure, fluid intake and output closely if using oxytocin for induction; fetal monitoring is strongly recommended. Assess labor

O X Y T O C I N

Genitourinary Drugs

contractions : fetal heart tones frequency, duration, intensity of contractions; notify physician if fetal heart tone increase or decrease significantly or if contractions are longer than 1 min; turn patient on left side to increase oxygen to fetus. and symptoms of water intoxications: confusion, anuria, drowsiness, headache notify

Assess signs

initiation of milk let down(nasal)